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Oral Presentations 9collection phases. These patterns were similar between transplant
teams caring for adult or pediatric donors and recipients. Among
responding centers, it appears that medical management of recipi-
ents and their related donors by the same provider is common, and
may not be viewed as a potential conflict-of-interest. Whether this
potential conflict-of-interest affects donor care is unclear, and
deserves further investigation.
Survey Responses *
Medical Informed Medical
Clearance Consent ManagementProvider responsible for donor care
Internist/Family Practitioner 1 (1) 0 (.) 2 (2)
Pediatrician 5 (6) 1 (1) 3 (3)
Heme/Onc Physician 5 (6) 2 (2) 2 (2)
Transplant Physician 71 (82) 72 (83) 78 (90)
Mid-level Provider 3 (3) 7 (8) 2 (2)
Nurse 0 (.) 3 (3) 0 (.)
Missing 2 (2) 2 (2) 2 (2)Role of donor provider in
care of Recipient
Simultaneous responsibility
for recipient’s care25 (29) 31 (36) 35 (40)May be involved in recipient’s care 38 (44) 35 (40) 32 (37)
Not involved in recipient’s care 16 (18) 17 (20) 14 (16)
Not involved in transplant
program or recipient’s care6 (7) 2 (2) 4 (5)Missing 2 (2) 2 (2) 2 (2)*No. Responding Centers (%).17
BK VIRUS INFECTION IS ASSOCIATED WITH HEMATURIA AND RENAL
IMPAIRMENT IN RECIPIENTS OF ALLOGENEIC HEMATOPOETIC STEM
CELL TRANSPLANTS
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BK virus (BKV) is an important pathogen and cause of nephrop-
athy in recipients of renal transplants, but its clinical significance in
patients (pts) following hematopoetic stem cell transplantation
(HSCT) is less well described. Over a 16 month period we prospec-
tively measured BKV in the blood and urine of 124 pts who had
undergone allogeneic HSCT [HLA-identical donor (n 5 70), alter-
native-donor (HLA-mismatched-related, matched-unrelated, or
cord) (n 5 54)] between 1998–2007 and who were receiving
in- or outpatient post-transplant care. Most pts (73%) received
alemtuzumab-containing regimens. BK viruria was manifest at
some time in 64.8% of pts; 16.9% developed BK viremia. All pts
with BK viremia also had viruria. BK viruria developed at a median
time post-HSCT of 24 d (range 3–138 d), while viremia was de-
tected at a significantly longer median time of 128 d (range 62–
307 d) (P\0.0001). Among clinical factors (disease, transplant
type, alemtuzumab use, CMV viremia, GVHD, HLA C locus sta-
tus), only CMV viremia was significantly more common in pts with
BK viruria and viremia. Given the association of BKV with hemor-
rhagic cystitis, urinalyses from all pts were analyzed for the pres-
ence and number of red blood cells. There was a direct
relationship between higher median and maximum levels of urinary
BKV with both an increased occurrence, and greater degree, of mi-
croscopic hematuria (P\0.03). BK viremia was also associated with
the development of hematuria (P 5 0.03). Finally, BKV infection
was analyzed along with other clinical factors in relation to the de-
velopment of post-HSCT renal impairment. On multivariate anal-
ysis, only BK viremia (P 5 0.000001) and undergoing an
alternative-donor transplant (P 5 0.002) were independent predic-
tors of development of post-HSCT renal impairment, with BK
viremia associated with a median 1.62 mg/dL rise in creatinine
from the pre-transplant baseline. Two pts with BK viremia
developed biopsy-proven BKV nephropathy, with both requiring
hemodialysis. In summary, BK viruria is a common early findingin pts undergoing allogeneic HSCT, and higher urinary BKV levels
are directly related to increased hematuria. BK viremia occurs later
and less commonly, is associated with hematuria, and is an inde-
pendent predictor of worsening renal function post-HSCT. Inves-
tigation of whether prophylaxis against, or treatment of, BKV in the
post-HSCT setting mitigates the associated morbidities, especially
kidney injury, warrants prospective evaluation.18
HHV6 REACTIVATION IS AN IMPORTANT RISKFACTOR FOR POOR
OUTCOMES IN MYELOABLATIVE, BUT NOT IN NON-MYELOABLATIVE
TREATED ALLOGENEIC HSCT PATIENTS
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Background: Haematopoietic stem cell transplantation (HSCT)
is complicated by viral reactivations. Viral reactivations are major
complications after HSCT. The role of Human Herpesvirus type
6 (HHV6) in complications after HSCT remains unclear. We found
a strong association between HHV6 reactivation and poor outcome
after HSCT in children after myeloablative conditioning regimens.
Risk factors for the development of HHV6 reactivation in adults
are unknown.We investigated the association of HHV6 reactivation
and clinical outcomes.
Methods: In a retrospective cohort study (January 2005- Decem-
ber 2007), HHV6DNA loads in plasma were monitored by realtime
PCR in adult patients after allogeneic HSCT in two HSCT-centers
in the Netherlands (Utrecht and Rotterdam). Previously, Epstein
Barr virus (EBV)- and cytomegalovirus (CMV) DNA loads were
prospectively monitored in these patients. EBV- and CMV-reactiva-
tions were pre-emptive treated according to local guidelines. HHV6
reactivation was defined as viral DNA load $1000 cp/mL. Associa-
tions between outcomes and various variables (age, gender, HSCT
center, donor source, HLA match of donor and recipient, myeloa-
blative (MA) versus non-myeloablative (NMA) conditioning regi-
men, EBV- and CMV-reactivation) were analyzed using Cox
proportional hazard models.
Results: 108 patients (60 MA and 48 NMA recipients; 49
Utrecht and 59 Rotterdam) between 2005 and 2007 were in-
cluded (median age 40.1; range 18- 66 years). Median follow-
up was 20 (range 1.4–35.8) months. 16/60 (27%) MA patients
had HHV6 reactivation (mean 50323 cp/mL) compared to 2/
48 (4%) NMA patients with marginal HHV6 reactivation
(mean 1000 cp/mL). Median time of reactivation for HHV6 in
MA patients was 19 (range 10–35) days, compared to 14 and
35 days in the 2 NMA patients. In multivariate analysis, MA con-
ditioning was the only predictor for HHV6 reactivation (HR
0.15; 95%CI 0.03–0.65; p 5 0.012). In addition, HHV6 reactiva-
tion was the only predictor for grade $2 acute Graft versus
host disease (HR 6,2, 95%CI 2,8- 13,9; p 5 0.000) and
Transplantation related mortality (HR 3,9, 95% CI 1.4–10.7;
p 5 0.010).
Conclusions: Early HHV6 reactivation is more common after
MA than after NMA conditioning treatment and is associated with
poor survival and severe acute GvHD. Screening for HHV6 reacti-
vation might be important in the MA treated patients since early ini-
tiation of pre-emptive or prophylactic anti-viral treatment might
influence the outcomes.19
NATURAL KILLER (NK) CELLS ARE RESISTANT TO THE APOPTOTIC EF-
FECTS OF CORTICOSTEROIDS COMPARED TO T CELLS: IMPLICATIONS
FOR ADOPTIVE NK CELL THERAPY FOLLOWING ALLOGENEIC HCT
Ramanathan, M., Lundqvist, A., Yokoyama, H., Smith, A., Childs, R.
National Institute of Health, Bethesda, MD
In vivo animal data and preliminary data in humans show donor
NK cells can mediate antitumor effects against malignancies when
adoptively infused following allogeneic hematopoietic cell
